Welcome to LookChem.com Sign In|Join Free

CAS

  • or
N-(4-Sulfanylphenyl)cyclopropanecarboxamide is a chemical compound that belongs to the class of organic compounds known as aniline and substituted anilines. It is an organic compound containing an aniline or a derivative thereof, where at least one hydrogen atom is replaced by an aryl group. N-(4-Sulfanylphenyl)cyclopropanecarboxamide is characterized by its high density, high boiling and melting points, and is typically presented as a white solid. It is soluble in various solvents and is primarily used in the research and development stage of pharmaceutical and chemical industries. Due to its potential environmental and human health implications, proper handling and storage are essential to prevent ingestion, inhalation, or skin contact.

639090-54-3 Suppliers

Post Buying Request

Recommended suppliersmore

  • Product
  • FOB Price
  • Min.Order
  • Supply Ability
  • Supplier
  • Contact Supplier
  • 639090-54-3 Structure
  • Basic information

    1. Product Name: N-(4-sulfanylphenyl)cyclopropanecarboxamide
    2. Synonyms: N-(4-sulfanylphenyl)cyclopropanecarboxamide;Cyclopropanecarboxylic acid N-(4-sulfanylphenyl)amide;N-(4-mercaptophenyl)cyclopropanecarboxamide
    3. CAS NO:639090-54-3
    4. Molecular Formula: C10H11NOS
    5. Molecular Weight: 193.27
    6. EINECS: N/A
    7. Product Categories: N/A
    8. Mol File: 639090-54-3.mol
  • Chemical Properties

    1. Melting Point: N/A
    2. Boiling Point: 408.6°C at 760 mmHg
    3. Flash Point: 200.9°C
    4. Appearance: /
    5. Density: 1.338
    6. Vapor Pressure: 6.93E-07mmHg at 25°C
    7. Refractive Index: 1.698
    8. Storage Temp.: 2-8°C
    9. Solubility: N/A
    10. PKA: 6.90±0.10(Predicted)
    11. CAS DataBase Reference: N-(4-sulfanylphenyl)cyclopropanecarboxamide(CAS DataBase Reference)
    12. NIST Chemistry Reference: N-(4-sulfanylphenyl)cyclopropanecarboxamide(639090-54-3)
    13. EPA Substance Registry System: N-(4-sulfanylphenyl)cyclopropanecarboxamide(639090-54-3)
  • Safety Data

    1. Hazard Codes: N/A
    2. Statements: N/A
    3. Safety Statements: N/A
    4. WGK Germany:
    5. RTECS:
    6. HazardClass: N/A
    7. PackingGroup: N/A
    8. Hazardous Substances Data: 639090-54-3(Hazardous Substances Data)

639090-54-3 Usage

Uses

Used in Pharmaceutical Research and Development:
N-(4-Sulfanylphenyl)cyclopropanecarboxamide is used as a research compound for the development of new pharmaceutical products. Its unique chemical structure and properties make it a valuable candidate for exploring potential therapeutic applications and drug interactions.
Used in Chemical Industry Research and Development:
In the chemical industry, N-(4-Sulfanylphenyl)cyclopropanecarboxamide is used as a research compound to investigate its potential applications in various chemical processes and reactions. Its high density and solubility in various solvents make it an interesting subject for further exploration and development.

Check Digit Verification of cas no

The CAS Registry Mumber 639090-54-3 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 6,3,9,0,9 and 0 respectively; the second part has 2 digits, 5 and 4 respectively.
Calculate Digit Verification of CAS Registry Number 639090-54:
(8*6)+(7*3)+(6*9)+(5*0)+(4*9)+(3*0)+(2*5)+(1*4)=173
173 % 10 = 3
So 639090-54-3 is a valid CAS Registry Number.
InChI:InChI=1/C10H11NOS/c12-10(7-1-2-7)11-8-3-5-9(13)6-4-8/h3-7,13H,1-2H2,(H,11,12)

639090-54-3SDS

SAFETY DATA SHEETS

According to Globally Harmonized System of Classification and Labelling of Chemicals (GHS) - Sixth revised edition

Version: 1.0

Creation Date: Aug 17, 2017

Revision Date: Aug 17, 2017

1.Identification

1.1 GHS Product identifier

Product name N-(4-sulfanylphenyl)cyclopropanecarboxamide

1.2 Other means of identification

Product number -
Other names 4-cyclopropanecarboxamidothiophenol

1.3 Recommended use of the chemical and restrictions on use

Identified uses For industry use only.
Uses advised against no data available

1.4 Supplier's details

1.5 Emergency phone number

Emergency phone number -
Service hours Monday to Friday, 9am-5pm (Standard time zone: UTC/GMT +8 hours).

More Details:639090-54-3 SDS

639090-54-3Relevant articles and documents

Tozasertib Analogues as Inhibitors of Necroptotic Cell Death

Hofmans, Sam,Devisscher, Lars,Martens, Sofie,Van Rompaey, Dries,Goossens, Kenneth,Divert, Tatyana,Nerinckx, Wim,Takahashi, Nozomi,De Winter, Hans,Van Der Veken, Pieter,Goossens, Vera,Vandenabeele, Peter,Augustyns, Koen

, p. 1895 - 1920 (2018/03/21)

Receptor interacting protein kinase 1 (RIPK1) plays a crucial role in tumor necrosis factor (TNF)-induced necroptosis, suggesting that this pathway might be druggable. Most inhibitors of RIPK1 are classified as either type II or type III kinase inhibitors. This opened up some interesting perspectives for the discovery of novel inhibitors that target the active site of RIPK1. Tozasertib, a type I pan-aurora kinase (AurK) inhibitor, was found to show a very high affinity for RIPK1. Because tozasertib presents the typical structural elements of a type I kinase inhibitor, the development of structural analogues of tozasertib is a good starting point for identifying novel type I RIPK1 inhibitors. In this paper, we identified interesting inhibitors of mTNF-induced necroptosis with no significant effect on AurK A and B, resulting in no nuclear abnormalities as is the case for tozasertib. Compounds 71 and 72 outperformed tozasertib in an in vivo TNF-induced systemic inflammatory response syndrome (SIRS) mouse model.

As inhibitors of Aurora kinases substituted pyrimidine derivatives

-

Paragraph 0326-0330, (2016/10/09)

The present invention relates to a substituted and aurora kinase-inhibiting pyrimidine derivative as represented by formula (I) or (Ia), tautomer, hydrate, solvate, ester or pharmaceutically acceptable salt thereof, and pharmaceutical composition comprising the compounds as active ingredients, as well as uses of the compounds and the pharmaceutical composition thereof in the preparation of drugs for protecting against, treating, curing or alleviating proliferative diseases of a patient.

COMPOUNDS AND METHODS OF USE THEREOF FOR TREATING NEURODEGENERATIVE DISORDERS

-

Paragraph 0217; 0218, (2014/07/08)

Compounds, compositions, kits and methods for treating conditions related to neurodegeneration or ocular disease, are disclosed.

Design and synthesis of minimalist terminal alkyne-containing diazirine photo-crosslinkers and their incorporation into kinase inhibitors for cell- and tissue-based proteome profiling

Li, Zhengqiu,Hao, Piliang,Li, Lin,Tan, Chelsea Y. J.,Cheng, Xiamin,Chen, Grace Y. J.,Sze, Siu Kwan,Shen, Han-Ming,Yao, Shao Q.

supporting information, p. 8551 - 8556 (2013/09/12)

Less is more: A minimalist "clickable" photo-crosslinker (see scheme) was incorporated with numerous small-molecule kinase inhibitors. The resulting probes were used for both in vitro (cell lysates) and in situ (live cells) proteome profiling, for large-scale identification of their potential cellular kinase targets and shows improved outcomes over previous probes. Copyright

DRUG DISCOVERY METHODS

-

Page/Page column 24, (2011/11/12)

The present invention relates to drug discovery methods, particularly methods for assaying compounds for activity as Aurora kinase inhibitors. This invention also relates to a pharmacophore describing compounds that are able to promote a conformational ch

TRIAZINE DERIVATIVES AND THEIR THERAPEUTICAL APPLICATIONS

-

Page/Page column 72-73, (2010/12/29)

Compounds of the formula (I) and formula (II) and pharmaceutically acceptable salts thereof.

TRIAZINE DERIVATIVES AND THEIR THERAPEUTICAL APPLICATIONS

-

Page/Page column 61, (2010/12/29)

The invention provides Triazine derivatives and further provides methods of using these compounds to modulate protein kinases and for treating diseases and conditions mediated by protein kinases.

AMINOPYRIMIDINES USEFUL AS KINASE INHIBITORS

-

Page/Page column 39, (2010/06/16)

The present invention relates to compounds useful as inhibitors of Aurora protein kinases. The invention also provides pharmaceutically acceptable compositions comprising those compounds and methods of using the compounds and compositions in the treatment

AURORA INHIBITORS CONTAINING A ZINC BINDING MOIETY

-

Page/Page column 56, (2009/08/14)

The present invention relates to Aurora inhibitors and their use in the treatment of cell proliferative diseases such as cancer. The said derivatives may further act as HDAC inhibitors.

KINASE INHIBITORS

-

Page/Page column 46, (2010/11/08)

Disclosed are protein kinase inhibitors of Formula Ia and Ib, compositions comprising such inhibitors, and methods of use, thereof. More particularly, these compounds and compositions are inhibitors of Aurora-A (Aurora-2) and Aurora-B (Aurora-1) protein k

Post a RFQ

Enter 15 to 2000 letters.Word count: 0 letters

Attach files(File Format: Jpeg, Jpg, Gif, Png, PDF, PPT, Zip, Rar,Word or Excel Maximum File Size: 3MB)

1

What can I do for you?
Get Best Price

Get Best Price for 639090-54-3